Du R, Zhang J, Lukas R, Tripathi S, Ahrendsen J, Curran M
Neuro Oncol. 2024; 27(1):33-49.
PMID: 39427326
PMC: 11726257.
DOI: 10.1093/neuonc/noae193.
Zhao K, Wu C, Li X, Niu M, Wu D, Cui X
Front Immunol. 2024; 15:1401528.
PMID: 38881902
PMC: 11176514.
DOI: 10.3389/fimmu.2024.1401528.
Moon S, Han M, Ryu G, Shin S, Lee J, Lee C
Int J Mol Sci. 2023; 24(20).
PMID: 37894750
PMC: 10606340.
DOI: 10.3390/ijms242015072.
Soliman A, Elzarkaa A, Malik E
Adv Exp Med Biol. 2021; 1330:21-32.
PMID: 34339028
DOI: 10.1007/978-3-030-73359-9_2.
Choi K, Kim A, Kim J, Kim K, Hwang C, Lee S
J Ovarian Res. 2020; 13(1):65.
PMID: 32513298
PMC: 7278194.
DOI: 10.1186/s13048-020-00667-y.
Comment on 'BAG-1 as a biomarker in early breast cancer prognosis: a systematic review with meta-analyses'.
Sauerbrei W, Haeussler T
Br J Cancer. 2018; 118(8):1152-1153.
PMID: 29540774
PMC: 5931108.
DOI: 10.1038/s41416-018-0023-z.
BAG-1 as a biomarker in early breast cancer prognosis: a systematic review with meta-analyses.
Papadakis E, Reeves T, Robson N, Maishman T, Packham G, Cutress R
Br J Cancer. 2017; 116(12):1585-1594.
PMID: 28510570
PMC: 5518859.
DOI: 10.1038/bjc.2017.130.
BRCA1-IRIS overexpression promotes and maintains the tumor initiating phenotype: implications for triple negative breast cancer early lesions.
Sinha A, Paul B, Sullivan L, Sims H, El Bastawisy A, Yousef H
Oncotarget. 2017; 8(6):10114-10135.
PMID: 28052035
PMC: 5354646.
DOI: 10.18632/oncotarget.14357.
Clinicopathological analysis of CD44 and CD24 expression in invasive breast cancer.
Jang M, Kang H, Jang K, Paik S, Kim W
Oncol Lett. 2016; 12(4):2728-2733.
PMID: 27698848
PMC: 5038856.
DOI: 10.3892/ol.2016.4987.
The Progress and Prospects of Putative Biomarkers for Liver Cancer Stem Cells in Hepatocellular Carcinoma.
Xiang Y, Yang T, Pang B, Zhu Y, Liu Y
Stem Cells Int. 2016; 2016:7614971.
PMID: 27610139
PMC: 5005617.
DOI: 10.1155/2016/7614971.
CD24 genetic variants contribute to overall survival in patients with gastric cancer.
Jia Z, Wang L, Cao X, Wang C, Cao D, Wu X
World J Gastroenterol. 2016; 22(7):2373-82.
PMID: 26900300
PMC: 4735012.
DOI: 10.3748/wjg.v22.i7.2373.
CD24: from a Hematopoietic Differentiation Antigen to a Genetic Risk Factor for Multiple Autoimmune Diseases.
Tan Y, Zhao M, Xiang B, Chang C, Lu Q
Clin Rev Allergy Immunol. 2015; 50(1):70-83.
PMID: 25666875
DOI: 10.1007/s12016-015-8470-2.
Triple negative breast cancer initiating cell subsets differ in functional and molecular characteristics and in γ-secretase inhibitor drug responses.
Azzam D, Zhao D, Sun J, Minn A, Ranganathan P, Drews-Elger K
EMBO Mol Med. 2013; 5(10):1502-22.
PMID: 23982961
PMC: 3799576.
DOI: 10.1002/emmm.201302558.
CD44/CD24 as potential prognostic markers in node-positive invasive ductal breast cancer patients treated with adjuvant chemotherapy.
Adamczyk A, Niemiec J, Ambicka A, Mucha-Malecka A, Mitus J, Rys J
J Mol Histol. 2013; 45(1):35-45.
PMID: 23835592
DOI: 10.1007/s10735-013-9523-6.
Clinical-pathologic significance of cancer stem cell marker expression in familial breast cancers.
Bane A, Viloria-Petit A, Pinnaduwage D, Mulligan A, OMalley F, Andrulis I
Breast Cancer Res Treat. 2013; 140(1):195-205.
PMID: 23813303
PMC: 3706716.
DOI: 10.1007/s10549-013-2591-1.
The gene desert mammary carcinoma susceptibility locus Mcs1a regulates Nr2f1 modifying mammary epithelial cell differentiation and proliferation.
Smits B, Haag J, Rissman A, Sharma D, Tran A, Schoenborn A
PLoS Genet. 2013; 9(6):e1003549.
PMID: 23785296
PMC: 3681674.
DOI: 10.1371/journal.pgen.1003549.
Determination of 35 cell surface antigen levels in malignant pleural effusions identifies CD24 as a marker of disseminated tumor cells.
Yao X, Labelle M, Lamb C, Dugan J, Williamson C, Spencer D
Int J Cancer. 2013; 133(12):2925-33.
PMID: 23775727
PMC: 4107365.
DOI: 10.1002/ijc.28312.
CD24 expression as a marker for predicting clinical outcome in human gliomas.
Deng J, Gao G, Wang L, Wang T, Yu J, Zhao Z
J Biomed Biotechnol. 2012; 2012:517172.
PMID: 22500096
PMC: 3303885.
DOI: 10.1155/2012/517172.
CD24 offers a therapeutic target for control of bladder cancer metastasis based on a requirement for lung colonization.
Overdevest J, Thomas S, Kristiansen G, Hansel D, Smith S, Theodorescu D
Cancer Res. 2011; 71(11):3802-11.
PMID: 21482678
PMC: 4283788.
DOI: 10.1158/0008-5472.CAN-11-0519.
The CD44+/CD24- phenotype relates to 'triple-negative' state and unfavorable prognosis in breast cancer patients.
Giatromanolaki A, Sivridis E, Fiska A, Koukourakis M
Med Oncol. 2010; 28(3):745-52.
PMID: 20405247
DOI: 10.1007/s12032-010-9530-3.